Navigation Links
Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710
Date:4/11/2011

unication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Merck Forward-Looking Statement

This news release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements may include, but are not limited to, statements about the benefits of the merger between Merck and Schering-Plough, including future financial and operating results, the combined company's plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Merck's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.

The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that the expected synergies from the merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period; the impact of pharmaceutical industry regulation and health care legislation; the risk that the businesses will not be integrated successfully; disruption from the merger making it more difficult to maintain business and operational relationships; Merck's ability to accurately predict future market conditions; dependence on the effectiveness of Merck's patents and other protections for innovative products; the risk of new and changing regulation and health policies in the United States and internationally and the exposure to litigation and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
'/>"/>

SOURCE Intercell AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Raises Target Price to $3.22
2. Delcath to Update Investors on FDA Meeting
3. TPI Business and Development Profile Updated on OneMedDatabase
4. Dipexium Pharmaceuticals Updates Locilex™ Development Activities and Announces 2011 Milestones
5. NeoStem Provides Results for 2010 and an Update on Recent Activities
6. SCOLR Pharma, Inc. Reports 2010 Financial Results, Provides Updates on Advances in Nutritionals, OTC Drugs
7. Effient® Added to Updated ACCF/AHA Clinical Guidelines for ACS-PCI Patients with Unstable Angina and Non-ST Segment Myocardial Infarction
8. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2010 and to Provide a Business Update
9. Alexza Reports 2010 Fourth Quarter and Full Year Financial Results and Provides General Corporate Update
10. NewCardio to Conduct Corporate Update Conference Call on March 29, 2011
11. OXIS International to Hold Business Update Conference Call on March 22
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is investigating ... Inc. ("Advaxis" or the "Company") (NASDAQ: ADXS ... duties to shareholders. On January 21, 2015, ... that Advaxis had misrepresented the clinical data for its ...
(Date:1/23/2015)... Jan. 23, 2015  Now available for sale, The Armor1 ... that prevents ankle sprains by cushioning the ankle from ... securely around the outside of any shoe type and ... while still offering protection against sprains. With customers in ...
(Date:1/23/2015)... LAS VEGAS , Jan. 23, 2015 Cord Blood ... CBAI ) ("CBAI" or the "Company")  filed a Preliminary Proxy ... ( www.sec.gov ) today, and provides an update for shareholders ... authorized shares is requested. Dear Shareholders, ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method put together ... by up to 30lbs in less than 12 weeks without ... Stevenson, prompting an investigative review. , “Our Incredible Bulk ... formula that allows the body to pack on a massive ...
(Date:1/22/2015)... 22, 2015 The federal court overseeing thousands ... District Court, Southern District of West Virginia has upheld a ... proceeding’s first bellwether trial. In an Order dated January 21st, ... after finding that C.R. Bard had not proven a miscarriage ...
(Date:1/22/2015)... released a new blog post explaining the main features of ... Auto insurance quotes help many drivers find the best coverage ... an agent or visit an agency for price information. These ... http://autocarinsurancebest.com/ . , Every business who relies heavily on transportation ...
(Date:1/22/2015)... 22, 2015 A study recently ... flagship journal Medicine & Science in Sports & ... may help reduce gastrointestinal (GI) problems associated with ... Participants in the double-blind, placebo-controlled study took 10 ...
(Date:1/22/2015)... 22, 2015 Four years since the release of ... coincided with the marriage of Avasa & Matthew Love – the ... is scheduled for release through White Swan Records on February 24, ... is a sacred path available to all of us to walk ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
... the company that will become public from the planned ... today filed a second amendment to its Form 10 ... that includes information about its post-spin board of directors ... under a consent decree for its Alaris(R) infusion products. ...
... to Lowering Healthcare Costs and Expanding Viability and Adoption of ... Health professionals and patients alike have access ... stabilizing mounting healthcare costs by increasing compliance. MedApps, Inc. ... Food and Drug Administration for its expanded, flexible telehealth solution. ...
... a wide range of communication tools, including email, IM and ... coach as often as they want over a 12-month period ... than condition-focused approach to healthcare, with outreach driven by individual ... June 9 Alere LLC, a leader in ...
... in improving caregiver workflow in healthcare environments, today announced the ... its board of directors. , , "We are pleased ... help broaden the business and operating base as we meet ... "Both Bill and Carol will bring strong leadership skills, extensive ...
... alkaline pH - key to Focus, Performance, Recovery in ... June 9 AquaHydrate, the first high-performance ... through support of events and initiatives, including the famous ... to provide cellular hydration in the most demanding environments, ...
... in Phase 1a single ascending dose trial , ... dose trials are expected in second half 2009 , ... VRUS ) announced today that it had completed the ... ascending dose trial with PSI-7851, a nucleotide analog polymerase inhibitor ...
Cached Medicine News:Health News:CareFusion Announces Board of Directors, Progress on Alaris Consent Decree 2Health News:CareFusion Announces Board of Directors, Progress on Alaris Consent Decree 3Health News:CareFusion Announces Board of Directors, Progress on Alaris Consent Decree 4Health News:MedApps Receives FDA Clearance on a New Way to Bring Cost-Effective Remote Health Monitoring to More People 2Health News:Alere Introduces Industry's First 12-month Unlimited Health Coaching Program 2Health News:Alere Introduces Industry's First 12-month Unlimited Health Coaching Program 3Health News:ThinIdentity(TM) Announces Two New Board Members 2Health News:ThinIdentity(TM) Announces Two New Board Members 3Health News:The First High-Performance Sports Water, AquaHydrate, Targets Military Market by Supporting Events Including 'Mud Run' 2Health News:The First High-Performance Sports Water, AquaHydrate, Targets Military Market by Supporting Events Including 'Mud Run' 3Health News:The First High-Performance Sports Water, AquaHydrate, Targets Military Market by Supporting Events Including 'Mud Run' 4Health News:Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients 2Health News:Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients 3Health News:Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients 4
Standard Lipo-tubing...
... Screening, Supplemental Confirmatory (Western Blot): The assay ... antigens on their surface. The cells are ... glass slide. Fixed, uninfected T-cells are provided ... plasma sample with HIV- I antibodies comes ...
Perfect for physicians who prefer a Heavier and Longer tubing, permitting them maximum access around the OR table. 12 feet in length Sizes availabe to fit any vacuum canisters...
Inquire...
Medicine Products: